NewAmsterdam Pharma(NAMSW)
NARRDEN, NetherlandsPharmaceutical
Focus: NewAmsterdam Pharma is a publicly traded Dutch small-molecule pharmaceutical company focused on metabolic diseases, neurology, ophthalmology, cardiovascular, and gastroenterology indications. The company is in clinical-stage development with a lead program (Obicetrapib) in Phase 2/3 across multiple indications.
Profile data last refreshed 14h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Total Funding
$196M
Open Jobs
8
Should You Work at NewAmsterdam Pharma?
AI assessmentBest fit for clinical-stage professionals seeking Phase 3 upside and therapeutic diversity; less suitable for those prioritizing hiring velocity or near-term revenue momentum.
Why Work Here
- Lead asset Obicetrapib is advancing through Phase 3 trials in dyslipidemias and cardiovascular disease with near-term catalysts in 2026-2027.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
6 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$14M
Pipeline & Clinical Trials
Corrie Lipids Digital Health Program
Cardiovascular RiskClinical Trials (1)
NCT07478887Impact of the Corrie Lipids Digital Health Program on Lipid Optimization
N/AHelp build intelligence for NewAmsterdam Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.